Brainose Technologies

Nasal Delivery of Cannabis-derived Therapeutics

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
Brainose Technologies
03/07/2022
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
01/01/2017
"1-10"

Brainose Technologies has developed a nose-to-brain delivery system for cannabis-derived therapeutics for the treatment of central nervous system (CNS) indications. Brainose is currently developing a pharmaceutical-grade cannabinoid-based therapy with a focus on pain management for FDA and CE approval in the U.S. and Europe.



The company’s mission is to provide the huge population that benefits from cannabis-derived therapeutics with accessibility to these medications in a simple, safe, efficient, and friendly manner. Its products are designed to ensure precise and reproducible dose delivery.



Brainose was founded as a collaboration between Cann10, an accelerator focused on medical cannabis, and Nextar Chempharma Solutions, a veteran pharmaceutical company. Brainose has partnered with SipNose to further progress on its drug delivery platform.